Scientific Advisory Board


Guru Muralimohan, Ph.D.

Executive Director, Bayer Pharmaceuticals

Dr. Guru Muralimohan is a team Leader with a strong scientific background and broad commercial experience in global strategic marketing, new product planning, business development & licensing (BD&L), and market access.

He is currently Executive Director at Bayer Pharmaceuticals for Oncology Early Pipeline Commercialization team. In addition to his portfolio responsibilities, has is also the commercial lead for BD&L efforts and collaborates effectively with Research, Early Clinical Development, Regulatory, Marketing and Market Access on several cross-functional initiatives.

Prior to Bayer, Guru spent nine years at Boehringer Ingelheim where he worked in US and Global Marketing, US Market Access, and US Strategy & Operations roles. He also has management consulting experience where he led several projects for pharmaceutical, biotech and private equity companies on venture investing, new product planning, search & evaluation and business development & licensing.

Guru started his career at Xcellerex Inc, a Boston biotech backed by venture capital firms Kleiner Perkins and VantagePoint. In that role he made significant contributions to increase shareholder value eventually leading to acquisition by GE Healthcare.

Guru holds a PhD in Immunology from University of Connecticut Health Center where he explored the role of adaptive and innate immune system on tumor biology. He also holds an MBA from University of Connecticut, School of Business.